Core Viewpoint - The company reported strong revenue and profit growth for 2024 and Q1 2025, driven by government subsidies and expanding overseas markets [1][2][3][4]. Financial Performance - In 2024, the company achieved revenue of 16.54 billion, a year-on-year increase of 6.7%, and a net profit attributable to shareholders of 810 million, up 31.7% [1][3]. - Q4 2024 revenue reached 6.32 billion, growing 27.1% year-on-year, with a net profit of 190 million, a staggering increase of 2178.0% [1][3]. - For Q1 2025, revenue was 3.86 billion, reflecting an 11.1% year-on-year growth, and net profit was 470 million, up 59.4% [1][3]. Profitability Improvement - The company's gross margin improved by 1.9 percentage points to 46.5% in 2024, attributed to supply chain optimization and strong sales of high-margin products [3]. - In Q1 2025, gross and net profit margins increased by 2.5 and 3.7 percentage points to 49.7% and 12.3%, respectively, driven by the higher proportion of new products [3][4]. Market Dynamics - The government subsidy policy significantly boosted domestic demand, with the cleaning appliance sector seeing online sales growth of 43.9% in Q4 2024 [2][4]. - The company is well-positioned in both domestic and international markets, with European revenues growing by 51.6% and 64.0% for its brands in 2024 [4]. Future Outlook - The company is expected to continue its operational improvement, with strong domestic demand and ongoing international expansion [4]. - The company has committed to distributing at least 30% of its annual distributable profits in cash from 2025 to 2027, indicating strong investment value [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing rapid growth in overseas business and optimizing its global installed structure [5] - Revenue forecasts for 2025-2027 are projected at 51.63 billion, 59.61 billion, and 69.28 billion RMB, with year-on-year growth rates of 13.84%, 15.45%, and 16.22% respectively [6] - Net profit attributable to the parent company for the same period is expected to be 20.12 billion, 23.43 billion, and 27.38 billion RMB, with growth rates of 10.06%, 16.41%, and 16.85% respectively [6] - The current price-to-earnings (P/E) ratios are 21x, 18x, and 15x for the years 2025, 2026, and 2027 [6] Financial Performance Summary - In 2024, the company achieved a revenue of 45.35 billion RMB (yoy +15.41%) and a net profit of 18.28 billion RMB (yoy +10.57%) [8] - For Q1 2025, the company reported a revenue of 11.25 billion RMB (yoy +10.12%) and a net profit of 4.38 billion RMB (yoy +2.65%) [8] - The company’s gross margin for 2024 was 72.26%, a slight decrease of 0.86 percentage points year-on-year, primarily due to an increase in the sales proportion of large and medium-sized instruments [8] - The company plans to continue increasing its investment in chemiluminescence and in vitro diagnostic products, with the launch of higher throughput instruments [8] Market Position and Strategy - The company has established operational systems in 14 core countries overseas, with significant sales growth in the Indian market, which exceeded 200 million RMB in 2024 [8] - The domestic revenue reached 28.43 billion RMB in 2024, with a year-on-year growth of 9.32%, driven by the promotion of high-speed instruments and production lines [8] - The company aims to enhance its market share in large medical institutions, achieving a coverage rate of 44.93% in tertiary hospitals by the end of 2024 [8]